Procédé de préparation, contrôles de qualité et spécifications des immunosélections CD34+ : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
[en] CD34+ immunomagnetic positive selection allows for CD34+ hematopoietic progenitors separation from CD3+ lymphocytes subsets, usually from an apheresis product collected from a previously mobilized donor. This T-cell depleted stem cell graft is primarily intended for rare cases (around 2% of allotransplanted patients in France) of severe, persistent, symptomatic bi- or tri-cytopenia post-allotransplantation, in order to allow for hematologic reconstitution without increasing the risk of GvHD occurrence. Although semi-manual and complex, the process is of sufficient robustness to consistently generate a cellular product with distinctive features and specifications, based on iterative in-process quality controls, that are discussed within these guidelines.
Disciplines :
Hematology
Author, co-author :
Calmels, Boris; Institut Paoli-Calmettes, 13009 Marseille, France > Centre de thérapie cellulaire
Gautier, Eric; EFS Île-de-France, 94017 Créteil, France > Unité d’ingénierie et de thérapie cellulaire
Magnani, Alessandra; Hôpital Necker-Enfants Malades, 75015 Paris, France > Laboratoire de thérapie cellulaire génique
Magrin, Elisa; Hôpital Necker-Enfants Malades, 75015 Paris, France > Laboratoire de thérapie cellulaire génique
Mamez, Anne Claire; Hôpitaux universitaires de Genève, 1211 Genève, Suisse > Laboratoire de thérapie cellulaire
Vaissié, Alix; CHU de Lille, 59000 Lille, France > Plateforme de biothérapies
Yakoub-Agha, Ibrahim; Université de Lille, CHU de Lille, 59000 Lille, France > Infinite, U1286, Inserm
BAUDOUX, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Laboratoire de thérapie cellulaire et génique (LTCG)
Language :
French
Title :
Procédé de préparation, contrôles de qualité et spécifications des immunosélections CD34+ : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
Alternative titles :
[en] CD34+ cell selection methods, quality controls and expected results: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
Cornillon, J., Sicre de Fontbrune, F., Chantepie, S., Coiteux, V., Gauthier, J., Masouridi-Levrat, S., et al. Management of graft failure and erythroblastopenia in patients undergoing allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Bull Cancer 103:11S (2016), S248–S254.
Tipton, R., Yakoub-Agha, I., How we harmonize HSCT clinical practices among the SFGM-TC centers?. Bull Cancer 103:11S (2016), S193–S197.
Velier, M., Granata, A., Bramanti, S., Calmels, B., Furst, S., Legrand, F., et al. A matched-pair analysis reveals marginally reduced CD34+ cell mobilization on second occasion in 27 related donors who underwent peripheral blood stem cell collection twice at the same institution. Transfusion 59:11 (2019), 3442–3447.
Mohty, R., Brissot, E., Battipaglia, G., Ruggeri, A., Sestili, S., Mediavilla, C., et al. CD34. Curr Res Transl Med 67:3 (2019), 112–114.
Mainardi, C., Ebinger, M., Enkel, S., Feuchtinger, T., Teltschik, H.M., Eyrich, M., et al. CD34. Br J Haematol 180:1 (2018), 90–99.
Barba, P., Hilden, P., Devlin, S.M., Maloy, M., Dierov, D., Nieves, J., et al. Ex Vivo CD34. Biol Blood Marrow Transplant 23:3 (2017), 452–458.
Ghobadi, A., Fiala, M.A., Ramsingh, G., Gao, F., Abboud, C.N., Stockerl-Goldstein, K., et al. Fresh or Cryopreserved CD34. Biol Blood Marrow Transplant 23:7 (2017), 1072–1077.
Stroncek, D.F., Tran, M., Frodigh, S.E., David-Ocampo, V., Ren, J., Larochelle, A., et al. Preliminary evaluation of a highly automated instrument for the selection of CD34+ cells from mobilized peripheral blood stem cell concentrates. Transfusion 56:2 (2016), 511–517.
Spohn, G., Wiercinska, E., Karpova, D., Bunos, M., Hümmer, C., Wingenfeld, E., et al. Automated CD34+ cell isolation of peripheral blood stem cell apheresis product. Cytotherapy 17:10 (2015), 1465–1471.
Haen, S.P., Schumm, M., Faul, C., Kanz, L., Bethge, W.A., Vogel, W., Poor graft function can be durably and safely improved by CD34 ± selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation. J Cancer Res Clin Oncol 141:12 (2015), 2241–2251.
Askaa, B., Fischer-Nielsen, A., Vindeløv, L., Haastrup, E.K., Sengeløv, H., Treatment of poor graft function after allogeneic hematopoietic cell transplantation with a booster of CD34-selected cells infused without conditioning. Bone Marrow Transplant 49:5 (2014), 720–721.
Stasia, A., Ghiso, A., Galaverna, F., Raiola, A.M., Gualandi, F., Luchetti, S., et al. CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 20:9 (2014), 1440–1443.
Klyuchnikov, E., El-Cheikh, J., Sputtek, A., Lioznov, M., Calmels, B., Furst, S., et al. CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. Biol Blood Marrow Transplant 20:3 (2014), 382–386.
Keever-Taylor, C.A., Devine, S.M., Soiffer, R.J., Mendizabal, A., Carter, S., Pasquini, M.C., et al. Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. Biol Blood Marrow Transplant 18:5 (2012), 690–697.
Gonzalez-Vicent, M., Perez, A., Abad, L., Sevilla, J., Ramirez, M., Diaz, M.A., Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients. J Pediatr Hematol Oncol 32:3 (2010), e85–e90.
Larocca, A., Piaggio, G., Podestà, M., Pitto, A., Bruno, B., Di Grazia, C., et al. Boost of CD34 ± selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica 91:7 (2006), 935–940.
Ringhoffer, M., Wiesneth, M., Harsdorf, S., Schlenk, R.F., Schmitt, A., Reinhardt, P.P., et al. CD34 cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients. Br J Haematol 126:4 (2004), 527–535.
Elmaagacli, A.H., Peceny, R., Steckel, N., Trenschel, R., Ottinger, H., Grosse-Wilde, H., et al. Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood 101:2 (2003), 446–453.
Després, D., Flohr, T., Uppenkamp, M., Baldus, M., Hoffmann, M., Huber, C., et al. CD34+ cell enrichment for autologous peripheral blood stem cell transplantation by use of the CliniMACs device. J Hematother Stem Cell Res 9:4 (2000), 557–564.
Richel, D.J., Johnsen, H.E., Canon, J., Guillaume, T., Schaafsma, M.R., Schenkeveld, C., et al. Highly purified CD34+ cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients. Bone Marrow Transplant 25:3 (2000), 243–249.
